IRG to Communicate the Company's Clinical Development Programs
EMERYVILLE, CALIF., November 20 /CNW/ - NovaBay Pharmaceuticals, Inc.
(Amex & TSX: NBY), a biopharmaceutical company focused on developing
innovative product candidates targeting the treatment or prevention of a wide
range of infections in hospital and non-hospital environments, has retained
the New York City-based The Investor Relations Group, Inc. (IRG), to serve as
its investor relations and corporate communications firm.
"Having recently completed our initial public offering, we remain focused
on moving forward with our clinical development of non-antibiotic
anti-infective products targeting the treatment or prevention of a wide range
of infections in hospital and community environments," said Ron Najafi, Ph.D.,
Chairman and Chief Executive Officer of NovaBay. "With leading pharmaceutical
partners and several product candidates in the pipeline, we believe The
Investor Relations Group will play an integral role in communicating NovaBay's
message to the investment community and the general media."
About The Investor Relations Group, Inc.
The Investor Relations Group, Inc. (IRG) offers a full-service corporate
communications program designed to suit the many unique needs of small-cap
companies. The program utilizes a proprietary, targeted approach to reach
institutional investors, analysts, and the media-at-large. For further
information, please visit the company's website at
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on
developing innovative product candidates targeting the treatment or prevention
of a wide range of infections in hospital and non-hospital environments.
NovaBay has discovered and is developing a class of antimicrobial compounds,
which it has named Aganocide compounds, which are based upon small molecules
that are generated by white blood cells that defend the body against invading
pathogens. NovaBay believes that Aganocide compounds could form a platform on
which to create a variety of products to address differing needs in the
treatment and prevention of bacterial and viral infections, including
Methicillin-Resistant Staphylococcus aureus (MRSA). NovaBay has entered into a
licensing and research collaboration agreement with an affiliate of Alcon,
Inc. for use of the Aganocide compounds in the eye, ear and sinus and in
contact lens solutions and a license agreement with an affiliate of Kinetic
Concepts, Inc. for the use of NovaBay's NeutroPhase product in woundcare
NovaBay(TM), Aganocide(TM) and NeutroPhase(TM) are trademarks of NovaBay
Pharmaceuticals, Inc. All other trademarks and trade names are the property of
their respective owners.
For more information visit the Company's website at www.novabaypharma.com
Forward Looking Statement
This release contains forward-looking statements, which are based upon
management's current expectations, assumptions, estimates, projections and
beliefs. These statements include, but are not limited to, statements
regarding the role of IRG and the development and potential benefits of, and
the market opportunities for, NovaBay's product candidates. Forward-looking
statements involve known and unknown risks, uncertainties and other factors
that may cause actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking statements.
Factors that might cause or contribute to such differences include, but are
not limited to, risks and uncertainties relating to difficulties or delays in
discovery, development, testing, regulatory approval, production and marketing
of the company's product candidates, unexpected adverse side effects or
inadequate therapeutic efficacy of the product candidates, the uncertainty of
patent protection for the company's intellectual property or trade secrets,
the company's ability to obtain additional financing as necessary and
unanticipated research and development and other costs. The forward-looking
statements in this release speak only as of this date, and NovaBay disclaims
any intent or obligation to revise or update publicly any forward-looking
statement except as required by law.
For further information:
For further information: The Investor Relations Group Investor
Relations: Adam Holdsworth / Rachel Colgate / Erica Ruderman 212-825-3210 or
Media Relations: Janet Vasquez / Susan Morgenbesser 212-825-3210